Plus Therapeutics announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant. Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from this offering are expected to be approximately $15M, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share and will expire five years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 5,921,052 shares of common stock and/or warrants to purchase up to an additional 5,921,052 shares of common stock, or any combination thereof, solely to cover over-allotments, if any. The offering is expected to close on January 15, subject to satisfaction of customary closing conditions. Lake Street Capital Markets is acting as the sole underwriter for the offering.
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8.00 USD with a low forecast of 2.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PSTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PSTV is 8.00 USD with a low forecast of 2.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.239
Low
2.00
Averages
8.00
High
19.00
Current: 0.239
Low
2.00
Averages
8.00
High
19.00
Maxim
Maxim
Buy
downgrade
$3
2026-01-23
Reason
Maxim
Maxim
Price Target
$3
AI Analysis
2026-01-23
downgrade
Buy
Reason
Maxim lowered the firm's price target on Plus Therapeutics to $1.50 from $3 and keeps a Buy rating on the shares. The company's ReSPECT-LM Phase 2 dose-optimization study continues to enroll, with data expected in Q3, and following encouraging feedback from its recent Type B meeting with the FDA, Plus plans to advance into a potentially pivotal leptomeningeal metastases study after completion of the current dose-optimization phase, though the firm is adjusting its model to reflect the dilution from the company's recent financing, the analyst tells investors in a research note.
H.C. Wainwright
Sean Lee
Buy
downgrade
$2 -> $1
2026-01-23
Reason
H.C. Wainwright
Sean Lee
Price Target
$2 -> $1
2026-01-23
downgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee lowered the firm's price target on Plus Therapeutics to $1 from $2 and keeps a Buy rating on the shares. The firm cites diluting from the company's recent equity offering for the target cut. It sees a "catalyst-rich" 2026 for Plus Therapeutics.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PSTV
Unlock Now
H.C. Wainwright
Buy
downgrade
$3 -> $2
2025-11-03
Reason
H.C. Wainwright
Price Target
$3 -> $2
2025-11-03
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Plus Therapeutics to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution associated with the equity raise for the target drop.
D. Boral Capital
Jason Kolbert
Hold
to
Buy
upgrade
$5
2025-09-03
Reason
D. Boral Capital
Jason Kolbert
Price Target
$5
2025-09-03
upgrade
Hold
to
Buy
Reason
D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics to Buy from Hold with a $5 price target. The firm, which previously had lowered its rating in May on concerns that the company was likely to execute a reverse split, says it seems those concerns \"may have faded\" for the moment and also cites the progress the company has been making on the diagnostics side. With catalysts such as a diagnostics launch, the firm sees the stock being back up over the \"critical $1.00 mark,\" the analyst added.
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
